[The biological fate of 4-butyl-4-(beta-carboxypropionyloxymethyl)-1,2-diphenyl-3,5-pyrazolidinedione (suxibuzone), antiinflammatory drug. II. The biological fate of suxibuzone (SB) after daily oral administration (author's transl)].
D000284:Administration, Oral; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000378:metabolism*; D004285:Dogs; D004334:Drug Administration Schedule; D005260:Female; D008297:Male; D010653:Phenylbutazone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000378:metabolism; D051381:Rats
D000893:Anti-Inflammatory Agents; C003371:suxibuzone; D010653:Phenylbutazone